Investigating the effect of ranolazine on reducing the number of premature ventricular complexes (PVC) and associated clinical symptoms in patients with. Other and unspecified premature depolarization
Conditions
Interventions
Intervention 1: Intervention group: Ranolazine group: Receive ranolazine at a dose of 500 mg twice daily (BID). Patients in the ranolazine group (Group 1) will take ranolazine at a dose of 500 mg twic
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 years and above A candidate for drug therapy Written informed consent
Exclusion criteria
Exclusion criteria: Patients who are required to use QT prolonging drugs such as citalopram pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PVC Burden Reduction Rate. Timepoint: Before starting treatment and after completing 3 months of treatment. Method of measurement: PVC percentage during 24-48 hour Holter monitoring before and after the treatment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of clinical symptoms. Timepoint: Before treatment and after 3 months of treatment. Method of measurement: Assess the severity and frequency of clinical symptoms (palpitations, chest pain, shortness of breath, dizziness) using standard tools (such as rating scales or questionnaires specific to arrhythmias). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahboob Ansari Nasab
Hamedan University of Medical Sciences
Outcome results
None listed